SB18-023 Summary

• Allows pharmaceutical manufacturers and their representatives to engage in truthful promotion of off-label uses of FDA-approved prescription drugs, biological products, and devices.

• Defines "off-label use" as use of an FDA-approved product in a manner other than the use approved by the FDA.

• Defines "truthful promotion" as sharing information that is not misleading, not contrary to facts, and consistent with generally accepted scientific principles.

• Prohibits the state board from revoking, failing to renew, or taking action against a manufacturer's registration for engaging in truthful promotion of off-label uses.

• Clarifies that health insurance carriers and third-party payers are not required to provide coverage for the cost of off-label uses.